These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 23589315)

  • 1. Evaluation of the relationship between cetuximab therapy and corrected QT interval changes in patients with advanced malignancies from solid tumors.
    Deeken JF; Shimkus B; Liem A; Hill D; Gurtler J; Berghorn E; Townes L; Lu H; Trifan O; Zhang S
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1473-83. PubMed ID: 23589315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of arsenic trioxide on QT interval in patients with advanced malignancies.
    Barbey JT; Pezzullo JC; Soignet SL
    J Clin Oncol; 2003 Oct; 21(19):3609-15. PubMed ID: 14512391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Onartuzumab with or without bevacizumab in combination with weekly paclitaxel does not prolong QTc or adversely affect other ECG parameters in patients with locally recurrent or metastatic triple-negative breast cancer.
    Borin MT; Chen M; Mocci S; Rubets I; Chittenden J; Aldairy W; Stroh M
    Cancer Chemother Pharmacol; 2015 Feb; 75(2):401-10. PubMed ID: 25542267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methadone maintenance, QTc and torsade de pointes: who needs an electrocardiogram and what is the prevalence of QTc prolongation?
    Mayet S; Gossop M; Lintzeris N; Markides V; Strang J
    Drug Alcohol Rev; 2011 Jul; 30(4):388-96. PubMed ID: 21355918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sugammadex is not associated with QT/QTc prolongation: methodology aspects of an intravenous moxifloxacin-controlled thorough QT study.
    de Kam PJ; van Kuijk J; Smeets J; Thomsen T; Peeters P
    Int J Clin Pharmacol Ther; 2012 Aug; 50(8):595-604. PubMed ID: 22735462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings.
    Noel GJ; Goodman DB; Chien S; Solanki B; Padmanabhan M; Natarajan J
    J Clin Pharmacol; 2004 May; 44(5):464-73. PubMed ID: 15102866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the effect of necitumumab on the corrected QT interval in patients with advanced solid tumors.
    Smith DC; Powderly J; Lee JJ; Shepard DR; Wallin J; Chaudhary A; Chao GY; Ng WT; Mitchell MI; Grau G; Kurek R; LoRusso P
    Cancer Chemother Pharmacol; 2016 Aug; 78(2):271-80. PubMed ID: 27312733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the effect of the EGFR antibody-drug conjugate ABT-414 on QT interval prolongation in patients with advanced solid tumors likely to over-express EGFR.
    Munasinghe WP; Mittapalli RK; Li H; Hoffman DM; Holen KD; Menon RM; Xiong H
    Cancer Chemother Pharmacol; 2017 May; 79(5):915-922. PubMed ID: 28349167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation and management of cardiac safety using the electrocardiogram in oncology clinical trials: focus on cardiac repolarization (QTc interval).
    Morganroth J; Shah RR; Scott JW
    Clin Pharmacol Ther; 2010 Feb; 87(2):166-74. PubMed ID: 20010556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study.
    Hulhoven R; Rosillon D; Bridson WE; Meeus MA; Salas E; Stockis A
    Clin Ther; 2008 Feb; 30(2):260-70. PubMed ID: 18343264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Late potentials and QT dispersion after high-dose chemotherapy in patients with non-Hodgkin lymphoma.
    Kuittinen T; Jantunen E; Vanninen E; Mussalo H; Nousiainen T; Hartikainen J
    Clin Physiol Funct Imaging; 2010 May; 30(3):175-80. PubMed ID: 20132128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 1 Study to Evaluate the Effect of the Investigational Anticancer Agent Sapanisertib on the QTc Interval in Patients With Advanced Solid Tumors.
    Patel C; Goel S; Patel MR; Rangachari L; Wilbur JD; Shou Y; Venkatakrishnan K; Lockhart AC
    Clin Pharmacol Drug Dev; 2020 Oct; 9(7):876-888. PubMed ID: 32488989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer.
    Cooney MM; Radivoyevitch T; Dowlati A; Overmoyer B; Levitan N; Robertson K; Levine SL; DeCaro K; Buchter C; Taylor A; Stambler BS; Remick SC
    Clin Cancer Res; 2004 Jan; 10(1 Pt 1):96-100. PubMed ID: 14734457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased incidence of QT interval prolongation in a population receiving lower doses of methadone maintenance therapy.
    Roy AK; McCarthy C; Kiernan G; McGorrian C; Keenan E; Mahon NG; Sweeney B
    Addiction; 2012 Jun; 107(6):1132-9. PubMed ID: 22168435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Corrected-QT intervals as related to methadone dose and serum level in methadone maintenance treatment (MMT) patients: a cross-sectional study.
    Peles E; Bodner G; Kreek MJ; Rados V; Adelson M
    Addiction; 2007 Feb; 102(2):289-300. PubMed ID: 17222284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors.
    Tan AR; Moore DF; Hidalgo M; Doroshow JH; Poplin EA; Goodin S; Mauro D; Rubin EH
    Clin Cancer Res; 2006 Nov; 12(21):6517-22. PubMed ID: 17065274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors.
    Lin CC; Calvo E; Papadopoulos KP; Patnaik A; Sarantopoulos J; Mita AC; Preston GG; Mita MM; Rodon J; Mays T; Yeh IT; O'Rourke P; Takimoto CH; Dancey JE; Chen H; Tolcher AW
    Cancer Chemother Pharmacol; 2009 May; 63(6):1065-71. PubMed ID: 18795291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent.
    McKeage MJ; Fong P; Jeffery M; Baguley BC; Kestell P; Ravic M; Jameson MB
    Clin Cancer Res; 2006 Mar; 12(6):1776-84. PubMed ID: 16551862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Literature review and pilot studies of the effect of QT correction formulas on reported beta2-agonist-induced QTc prolongation.
    Milic M; Bao X; Rizos D; Liu F; Ziegler MG
    Clin Ther; 2006 Apr; 28(4):582-90. PubMed ID: 16750469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeling the effect of sevoflurane on corrected QT prolongation: a pharmacodynamic analysis.
    Han DW; Park K; Jang SB; Kern SE
    Anesthesiology; 2010 Oct; 113(4):806-11. PubMed ID: 20808206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.